These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3529484)

  • 21. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs.
    Davì G; Pinto A; Francavilla G; Paterna S; Campisi D; Strano A
    Thromb Res; 1985 Oct; 40(2):275-81. PubMed ID: 2933846
    [No Abstract]   [Full Text] [Related]  

  • 22. [The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
    Andriani A; Chiappetta MG; Fabiani M; Mosiello G; Beni A
    Clin Ter; 1983 Feb; 104(3):219-22. PubMed ID: 6345050
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of ticlopidine, a new platelet aggregation inhibitor in man.
    Thebault JJ; Blatrix CE; Blanchard JF; Panak EA
    Clin Pharmacol Ther; 1975 Oct; 18(4):485-90. PubMed ID: 1100310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
    Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
    de Gaetano G; Bertelé V
    Arq Bras Cardiol; 1983 Dec; 41(6):425-7. PubMed ID: 6678584
    [No Abstract]   [Full Text] [Related]  

  • 26. The influence of ticlopidine on the natural course of retinal vein occlusion.
    Houtsmuller AJ; Vermeulen JA; Klompe M; Zahn KJ; Henkes HE; Baarsma GS; Tijssen J
    Agents Actions Suppl; 1984; 15():219-29. PubMed ID: 6385648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study).
    Mirouze J
    Agents Actions Suppl; 1984; 15():230-58. PubMed ID: 6385649
    [No Abstract]   [Full Text] [Related]  

  • 28. In vivo study of platelet aggregation in rats.
    Pinon JF
    J Pharmacol Methods; 1984 Sep; 12(2):79-84. PubMed ID: 6536819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of heparin and prostacyclin on blood platelet activity].
    Kisiel S; Myśliwiec M; Jakubowska I; Rydzewski A
    Pol Tyg Lek; 1983 Jun; 38(24):717-20. PubMed ID: 6359097
    [No Abstract]   [Full Text] [Related]  

  • 30. Heparin counteracts the antiaggregating effect of prostacyclin by potentiating platelet aggregation.
    Bertelé V; Roncaglioni MC; Donati MB; de Gaetano G
    Thromb Haemost; 1983 Apr; 49(2):81-3. PubMed ID: 6346573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Platelet aggregation and antiaggregant drugs].
    Andriani A; Chiappetta MG; Fabiani M
    Recenti Prog Med; 1982 Nov; 73(5):537-42. PubMed ID: 6761807
    [No Abstract]   [Full Text] [Related]  

  • 32. Platelet inhibitory activity of prostacyclin in the presence of erythrocytes as studied with the impedance aggregometer.
    Gresele P; Deckmyn H; Arnout J; Vermylen J
    Br J Haematol; 1984 May; 57(1):171-3. PubMed ID: 6372851
    [No Abstract]   [Full Text] [Related]  

  • 33. Antithrombotic effects of sodium salt of 17(R)-methyl-20-isopropylidenecarbacyclin in the arteriole of the hamster cheek pouch.
    Morita A; Endo K; Mori M; Akiyama K; Kohata K; Kobayashi S
    Arzneimittelforschung; 1986 Apr; 36(4):676-9. PubMed ID: 3521615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity.
    Gurbel PA; Bliden KP
    Platelets; 2003; 14(7-8):481-3. PubMed ID: 14713517
    [No Abstract]   [Full Text] [Related]  

  • 35. Design, synthesis, and inhibition of platelet aggregation for some 1-o-chlorophenyl-1,2,3,4-tetrahydroisoquinoline derivatives.
    Yang J; Hua WY; Wang FX; Wang ZY; Wang X
    Bioorg Med Chem; 2004 Dec; 12(24):6547-57. PubMed ID: 15556771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-specific inhibition of ADP-induced platelet antiaggregation by clopidogrel in vitro.
    Herbert JM; Savi P
    Thromb Haemost; 1999 Jul; 82(1):156-7. PubMed ID: 10456476
    [No Abstract]   [Full Text] [Related]  

  • 37. [Platelet sensitivity to prostacyclin (PGI2) in patients with juvenile-onset diabetes mellitus (author's transl)].
    Klein K; Sinzinger H; Schernthaner G; Silberbauer K; Prager R
    Wien Klin Wochenschr; 1981 Jul; 93(14):460-2. PubMed ID: 7023074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Platelet antiaggregants and bleeding time lengthening: management in the preoperative period].
    Thébault JJ; Blatrix C; Blanchard J; Panak E
    Agressologie; 1983 Dec; 24(12):609-11. PubMed ID: 6670692
    [No Abstract]   [Full Text] [Related]  

  • 39. The interactions of ticlopidine and aspirin in normal subjects.
    Thebault JJ; Blatrix CE; Blanchard JF; Panak EA
    J Int Med Res; 1977; 5(6):405-11. PubMed ID: 590598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ticlopidine on human platelet responsiveness ex vivo: comparison with aspirin.
    Nunn B; Lindsay R
    Thromb Res; 1980 Jun; 18(6):807-813. PubMed ID: 7414564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.